Dataset Information

The association between rs12885713 polymorphism in CALM1 and risk of osteoarthritis: A meta-analysis of case-control studies.

ABSTRACT: OBJECTIVE:The single nucleotide polymorphism (SNP) rs12885713 of calmodulin 1 gene (CALM1) has been reported to involve in the etiology of osteoarthritis (OA) in several association studies with limited sample size and conflicting results. The purpose of the present systematic review and meta-analysis was to evaluate and synthesize the currently available data on the correlation between rs12885713 and OA susceptibility. METHODS:Six electronic databases including PubMed, EMBASE, ISI Web of Science, CNETRAL, CNKI, and Wanfang were systematically retrieved to identify relevant observational articles published before October 2017. Summary odds ratios (ORs) and corresponding 95% confidence intervals (95% CIs) were calculated to indicate the association between CALM1 polymorphism and OA. Risk of bias was assessed through the Newcastle-Ottawa Scale. Predetermined subgroups and sensitivity analyses were performed using the RevMan 5.3 software. Publication bias was evaluated by Egger and Begg tests. RESULTS:Overall, 5 case-control studies involving 2183 OA patients 2654 healthy control subjects satisfied the meta-analysis. Recessive model was confirmed to be the best-matching genetic model (TT?+?TC versus CC). The pooled outcomes indicated that rs12885713 SNP was not significantly associated with OA vulnerability (OR 1.11, 95% CI 0.97, 1.27; P?=?.12). When stratified by different genders, OA sites, and population descents respectively, still non-significant associations were found. CONCLUSION:Based on the findings of our present study, the rs12885713 polymorphism of CALM1 did not appear to be associated with OA predisposition.

SUBMITTER: Shi J

PROVIDER: S-EPMC6133536 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

The association between rs12885713 polymorphism in CALM1 and risk of osteoarthritis: A meta-analysis of case-control studies.

Shi Jia J Gao Shu-Tao ST Lv Zheng-Tao ZT Sheng Wei-Bin WB Kang Hao H

Medicine 20180901 36

<h4>Objective</h4>The single nucleotide polymorphism (SNP) rs12885713 of calmodulin 1 gene (CALM1) has been reported to involve in the etiology of osteoarthritis (OA) in several association studies with limited sample size and conflicting results. The purpose of the present systematic review and meta-analysis was to evaluate and synthesize the currently available data on the correlation between rs12885713 and OA susceptibility.<h4>Methods</h4>Six electronic databases including PubMed, EMBASE, IS ...[more]

PMID: 30200150

Similar Datasets

Project description:Several studies have inspected the relationship between rs735482 polymorphism and the risk of some human cancers, but the findings remain controversial. We designed this meta-analysis to validate the association between rs735482 polymorphism and cancer risk. All articles were published before September 1, 2018 and searched in Pubmed, Embase, Web of Science, China National Knowledge Infrastructure, WangFang, and Chinese BioMedical databases, STATA 12.0 software was used for statistical analysis, which provides reasonable data and technical support for this article. A total of 10 studies were included in the meta-analysis, including 2652 cancer cases and 3536 rs735482 polymorphic controls. Data were directly extracted from these studies and odds ratios with 95% confidence intervals were computed to estimate the strength of the association. By pooling all eligible studies, the rs735482 polymorphism showed no significant association with susceptibility of several cancers in all the five genetic models (the allelic model: OR = 1.019, 95% CI: 0.916-1.134, P = .731). In addition, another adjusted OR data showed a significant increased risk between the rs735482 and susceptibility of several cancers (the codominant model BB vs AA: OR = 1.353, 95% CI: 1.033-1.774, P = .028) and the stratification analysis by ethnicity indicated the rs735482 is associated with an increased risk of cancer in Chinese group (BB vs AA, OR = 1.391, 95% CI = 1.054-1.837, P = .020; AB+BB vs AA OR = 1.253, 95% CI = 1.011-1.551, P = .039). However, the ERCC1 rs735482 is associated with a decreased risk of cancer in Italian group (AB vs AA, OR = 0.600, 95% CI = 0.402-0.859, P = .012; AB + BB vs AA, OR = 0.620, 95% CI = 0.424-0.908, P = .014). The results of this meta-analysis do not support the association between rs735482 polymorphism and cancer risk. But stratified analysis showed that rs735482 significantly increased the risk of cancer in Chinese while decreased the risk of cancer in Italian. Because of the limited number of samples, larger and well-designed researches are needed to estimate this association in detail.

Project description:Statin-related myopathy is an important adverse effect of statin which is classically unpredictable. The evidence of association between solute carrier organic anion transporter 1B1 (SLCO1B1) gene T521C polymorphism and statin-related myopathy risk remained controversial. This study aimed to investigate this genetic association. Databases of PubMed, EMBASE, Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database, and Wanfang Data were searched till June 17, 2015. Case-control studies investigating the association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk were included. The Newcastle-Ottawa Scale (NOS) was used for assessing the quality of included studies. Data were pooled by odds ratios (ORs) and their 95% confidence intervals (CIs). Nine studies with 1360 cases and 3082 controls were included. Cases of statin-related myopathy were found to be significantly associated with the variant C allele (TC + CC vs TT: OR = 2.09, 95% CI = 1.27-3.43, P = 0.003; C vs T: OR = 2.10, 95% CI = 1.43-3.09, P < 0.001), especially when statin-related myopathy was defined as an elevation of creatine kinase (CK) >10 times the upper limit of normal (ULN) or rhabdomyolysis (TC + CC vs TT: OR = 3.83, 95% CI = 1.41-10.39, P = 0.008; C vs T: OR = 2.94, 95% CI = 1.47-5.89, P = 0.002). When stratified by statin type, the association was significant in individuals receiving simvastatin (TC + CC vs TT: OR = 3.09, 95% CI = 1.64-5.85, P = 0.001; C vs T: OR = 3.00, 95% CI = 1.38-6.49, P = 0.005), but not in those receiving atorvastatin (TC + CC vs TT: OR = 1.31, 95% CI = 0.74-2.30, P = 0.35; C vs T: OR = 1.33, 95% CI = 0.57-3.12, P = 0.52). The available evidence suggests that SLCO1B1 gene T521C polymorphism is associated with an increased risk of statin-related myopathy, especially in individuals receiving simvastatin. Thus, a genetic test before initiation of statins may be meaningful for personalizing the treatment.

Dataset Information

The association between rs12885713 polymorphism in CALM1 and risk of osteoarthritis: A meta-analysis of case-control studies.

Publications

The association between rs12885713 polymorphism in CALM1 and risk of osteoarthritis: A meta-analysis of case-control studies.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets